Germany’s health minister has given regulatory approval for the first trial in the country of a vaccine for the coronavirus.
Jens Spahn says the trial will involve 200 people ages 18-55. He cautions the process of fully testing the vaccine would take months.
Germany’s regulatory authority, the Paul Ehrlich Institute, approved the trial for an RNA-based vaccine being jointly developed by BioNTech and Pfizer. Regulatory approval for trials is also being sought in the United States and China.
Numerous companies are racing to develop a vaccine for the coronavirus that has infected more than 2.5 million people worldwide and caused at least 178,000 deaths in the past four months.
— AP
Is our work important to you?
Does The Times of Israel give you valuable insight into Israel and the Jewish world? If so, please join The Times of Israel Community. For as little as $6/month, you will:
Join the Times of Israel Community
Join our Community
Already a member? Sign in to stop seeing this
You’re serious. We appreciate that!
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we come to work every day - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this
comments